Abstract:【Objective】 To investigate the efficacy and safety of ticagrelor combined with atorvastatin in patients with coronary heart disease (CHD) complicated with hyperlipidemia. 【Methods】 A total of 104 patients with CHD complicated with hyperlipidemia treated at Sanguanmiao Zhengshang Road Community Health Service Center, the Second Affiliated Hospital of Zhengzhou University from January 2023 to March 2025 were enrolled and divided into the control group (atorvastatin treatment) and the observation group (ticagrelor combined with atorvastatin treatment) by random number table method, with 52 cases in each group. Clinical efficacy, blood-lipid levels [high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), total cholesterol (TC)], cardiac function indicators [cardiac output, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDD)], laboratory indicators [vascular endothelial growth factor (VEGF), high-sensitivity C-reactive protein (hs-CRP), homocysteine (Hcy)] and incidence of adverse reactions were compared between the two groups. 【Results】 After 6-month follow-up, the total clinical effective rate of the observation group was 92.31% (48/52), which was higher than 76.92% (40/52) of the control group (χ2=4.727, P<0.05). After treatment, serum levels of LDL-C, TG and TC decreased, while serum HDL-C level increased in both groups (all P<0.05). There were no significant inter-group differences in HDL-C, LDL-C, TG and TC after treatment (all P>0.05). After treatment, cardiac output and LVEF increased, whereas LVDD decreased in both groups; the observation group had higher cardiac output and LVEF and lower LVDD compared with the control group (all P<0.05). After treatment, serum VEGF level increased, while hs-CRP and Hcy levels decreased in both groups. The observation group presented higher VEGF level and lower hs-CRP and Hcy levels than the control group (all P<0.05). The incidence of adverse reactions was 9.62% (5/52) in the observation group and 11.54% (6/52) in the control group, without statistically significant difference (χ2=0.102, P>0.05). 【Conclusion】 Ticagrelor combined with atorvastatin achieves favorable efficacy for patients with coronary heart disease complicated with hyperlipidemia. It can effectively improve cardiac function and enhance vascular repair capacity with good safety profile.
朱晓黎, 朱素贞, 李丹利, 王博, 杨恩波. 替格瑞洛联合阿托伐他汀治疗冠心病合并高脂血症患者的效果与安全性[J]. 医学临床研究, 2026, 43(8): 1249-1252.
ZHU Xiaoli, ZHU Suzhen, LI Danli, WANG Bo, YANG Enbo. Efficacy and Safety of Ticagrelor Combined with Atorvastatin in Patients with Coronary Heart Disease Complicated with Hyperlipidemia. JOURNAL OF CLINICAL RESEARCH, 2026, 43(8): 1249-1252.